Biogen tops profit estimates as cost cuts take hold, Alzheimer's drug Leqembi launch picks up
by CNBC
CNBC— Alzheimer's drug Leqembi brought in approximately $19 million in sales for the quarter, up from the $10 million the drug generated last year.
CNBC—Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold. The company reiterated its full-year 2024 sales guidance of roughly $4 billion, which includes revenue from the expected launch of its RSV vaccine.
Yahoo Finance—3M beats profit estimates on price hikes, cost cuts. 3M said its dividend payout ratio is expected to be 40% of adjusted free cash flow, with a potential to increase over time following the spin off of its healthcare business. The company has benefited from steady price increases across categories, which have helped it offset inflation and slow demand in its electronics business. "We improved performance in our businesses through strong operational execution, completed the spin-off of Solventum, and finalized two major legal settlements,"...
Bloomberg—UPS Profit Tops Estimates as Efficiency Push Counters Labor Cost. United Parcel Service Inc. reported profit higher than analysts’ estimates as the courier’s headcount management and restructuring of its delivery routes began to bear fruit.